Redeye updates its estimates following Freemelt’s Q2 report, which came in weaker than expected due ...
Rovio's Q2 revenue was 5% below Infront consensus, whereas adjusted EBIT was in line.
The Q2 results were disappointing due to new project-related writedowns and higher-than-normal sickn...
After revisiting the Freja case following the Q2 report, we conclude: 1) Freja’s niche Org eID marke...
Redeye states that the Q2 report was weaker than expected, with external factors still hampering the...
Redeye comments on Evaxion’s second quarter report 2022.
Redeye provides its comments on CLS Q2’22 report. The report did not include any surprises, and we b...
100% organisk tillväxt i Q1 Candles meddelade i går att den organiska tillväxten för Q1 22/23 når ca...
Vi noterar hög aktivitet bland bolagets kliniska projekt och nu avser Active Biotech att fylla på ka...
Redeye retains its positive view on Transtema following a strong Q2 report.
Redeye will mute its sales expectations after another quarter with negative sequential sales growth.
Redeye comments on Freemelt’s Q2 results, which came in lower than expected, primarily due to a deli...
Aspo’s record high H1 results are to face headwinds in H2, but in our view EBIT may well stay above ...
Redeye states that the Q2 report was better than feared after the profit warning, while still below ...
Solteq’s Q2 fell short our expectations, with revenue at EUR 17.
Netcompany reported another set of disappointing quarterly results.
Redeye comments on G5’s Q2-results where topline came in slightly lower than expected while profit w...
Q2 EBITA was 7% below Refinitiv consensus due to lower utilisation rates and higher costs, but some ...
Estimates slightly down on lower production guidance Continued progress on Block 56 Share discoun...
Acquires Networks Centre Holding Company in the UK Pays 8.
